CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Washington University School of Medicine
Servier
Daiichi Sankyo
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Shanghai Henlius Biotech
Seagen Inc.
Qurient Co., Ltd.
AstraZeneca
Seagen Inc.
Tizona Therapeutics, Inc
Essen Biotech
Genentech, Inc.
Nouscom SRL
H. Lee Moffitt Cancer Center and Research Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Takeda
RemeGen Co., Ltd.
Rutgers, The State University of New Jersey
ImmunityBio, Inc.
Amgen
Linnaeus Therapeutics, Inc.
Suzhou Transcenta Therapeutics Co., Ltd.
University of Pittsburgh
Cedars-Sinai Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rondo Therapeutics
Astellas Pharma Inc
Hanmi Pharmaceutical Company Limited
Sanofi
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
Hoosier Cancer Research Network
NuCana plc
University of Colorado, Denver
Mayo Clinic
Aprea Therapeutics
Imugene Limited
Duke University
MacroGenics
Merus B.V.
Sotio Biotech Inc.
Carisma Therapeutics Inc
NextCure, Inc.
Celularity Incorporated
National Cancer Center Hospital East
Essen Biotech
Inhibrx Biosciences, Inc
NGM Biopharmaceuticals, Inc